Ionizing radiation (IR) triggers mitochondrial overproduction of H2O2 and accumulation of lipid hydroperoxides leading to the induction of apoptotic and necroptotic cell death pathways. Given the high catalytic efficiency of the seleno-enzyme glutathione peroxidase (Gpx) toward reduction of lipid hydroperoxides and H2O2, we tested the potential of mitochondria-targeted derivatives of ebselen to mitigate the deleterious effects of IR. We report that 2-[[2-[4-(3-oxo-1,2-benzoselenazol-2-yl)phenyl]acetyl]amino]ethyl-triphenyl-phosphonium chloride (MitoPeroxidase 2) was effective in reducing lipid hydroperoxides, preventing apoptotic cell death, and, when administered 24 h postirradiation, increased the survival of mice exposed to whole body γ-irradiation.
Ionizing radiation (IR) triggers mitochondrial overproduction of H2O2 and accumulation of lipid hydroperoxides leading to the induction of apoptotic and necroptotic cell death pathways. Given the high catalytic efficiency of the seleno-enzyme glutathione peroxidase (Gpx) toward reduction of lipid hydroperoxides and H2O2, we tested the potential of mitochondria-targeted derivatives of ebselen to mitigate the deleterious effects of IR. We report that 2-[[2-[4-(3-oxo-1,2-benzoselenazol-2-yl)phenyl]acetyl]amino]ethyl-triphenyl-phosphonium chloride (MitoPeroxidase 2) was effective in reducing lipid hydroperoxides, preventing apoptotic cell death, and, when administered 24 h postirradiation, increased the survival of mice exposed to whole body γ-irradiation.
Exposure of eukaryotic cells to ionizing radiation (IR) results in
a burst of species with high energy (eaq–; H•, HO•, and O2–•) and indiscriminate reactivity with biomolecules,
including DNA, on the millisecond time scale.[1] Studies by Patt, Bacq, and others have established that aminothiols
such as cysteine and cysteamine protect mice from short-lived radiolytic
intermediates.[2−4] Humans, however, do not tolerate the doses of cysteine
and cysteamine, which would be required for analogous protection,
and the early hope that these compounds might be useful as radiation
protectors (RPs) has not been realized. These initial observations
have been followed by a research program under the auspice of the
Walter Reed Army Research Institute, which has led to the synthesis
of 4400 aminothiols and their assessment as RPs.[5] Structural variables in the synthesis of RPs were the length
and branching of the carbon chain that linked NH2, SH,
and OH functional groups. From this chemical library, only amifostine
(H2O3P–S–(CH2)2–NH–(CH2)3–NH2)
has found clinical applications.[6]The immediate burst of radicals upon exposure to IR is followed by
a dose-dependent and continuous mitochondrial overproduction of reactive
oxygen species.[7,8] These primary lethal effects of
IR, realized predominantly in rapidly proliferating hematopoietic
cells and gut epithelial cells, initiate secondary effects whereby
activated inflammatory cells massively generate reactive oxygen species
(ROSs) thus producing “friendly fire” and inducing new
waves of oxidation reactions culminating in apoptotic and nonapototic
cell death.[9] Among these secondary oxidants,
H2O2 and lipid hydroperoxides (LOOH) are most
prominent in setting-up the “peroxide tone” and perpetuating
enzymatic and nonenzymatic oxidations of critical biomolecules with
signaling functions. In particular, peroxidase functions of mitochondrial
intermembrane space hemoprotein, cytochrome c (cyt c), toward a mitochondria-specific
phospholipid, cardiolipin (CL), has been associated with the accumulation
of CL hydroperoxides required for the execution of mitochondrial apoptosis.[10] In addition, a group of cytosolic nonheme iron
proteins, lipoxygenases (LOX), catalyze oxygenation reactions yielding
hydroperoxides of free polyunsaturated fatty acids thus inducing necroptotic
and ferroptotic cell death signals.[11] Hence,
regulation of the levels of ROSs is important for the control of the
major radiation-induced cell death pathways.[12]The central regulator of LOOH is a seleno-enzyme, glutathione
peroxidase 4 (GPx4), whose deficiency leads to cell death.[12] GPx has been shown to impede mitochondrial apoptosis
via clearance of hydroperoxides of CL,[13,14] while overexpression
of mitochondrial catalase has been found to increase radioresistance
in vitro and in vivo.[15]Recently,
Tak and Park have reported that 2-phenyl-1,2-benzoselenazol-3-one
(ebselen; Scheme 1, 1), when administered
for 14 days prior to radiation, provides substantial protection against
killing and oxidative damage to mice exposed to whole-body irradiation
(WBI).[16] Ebselen is a multifunctional drug
that accumulates in the endoplasmic reticulum (ER),[17] reacts with cellular thiols, and mimics the activity of
glutathione peroxidase (GPx) by clearing H2O2 and LOOH (Scheme 1).[18] Following recent clinical trials for the prevention and treatment
of cardiovascular diseases, arthritis, stroke, and atherosclerosis,[18] ebselen has been included in the National Institutes
of Health Clinical Collection,[19] a chemical
library of bioavailable drugs considered clinically safe.
Scheme 1
Ebselen
Exhibits GPx-Like Activity
We have assessed the potential of the derivatives of ebselen
4-[4-(3-oxo-1,2-benzoselenazol-2-yl)phenoxy]butyl-triphenyl-phospho-nium
iodide (MitoPeroxidase 1; synthesized as reported in ref (20); Scheme 2) and 2-[[2-[4-(3-oxo-1,2-benzoselenazol-2-yl)phenyl]acetyl]amino]ethyl-triphenyl-phosphonium
chloride (MitoPeroxidase 2; Scheme 3, 10) to
act as radiation mitigators (RMs). Because under conditions of oxidative
stress sufficient concentrations of antioxidants at the sites of generation
of reactive metabolites are critical to protection from oxidative
damage, we have targeted the synthesis of ebselen derivatives that
selectively compartmentalize to mitochondria (Scheme 2).
Scheme 2
Design of Mitochondria-Specific Ebselen Derivatives
Scheme 3
Synthesis of MitoPeroxidase 2
Reagents and conditions: (a)
aq. NaNO2, HCl (18%), 0 °C; (b) Na2Se2, aq. NaOH, 40 °C (2 h), 55–63%; (c) SOCl2, DMF, reflux (1 h), >95%; (d) 2-(4-aminophenyl)acetic
acid, Et3N, CH3CN, 0 °C (1 h) to 25 °C
(3 h), 72–76%; (e) (Ph)3P+CH2CH2NH2, DCC, 0 °C (1 h) to 25 °C
(4 h), 80–85%.
Synthesis of MitoPeroxidase 2
Reagents and conditions: (a)
aq. NaNO2, HCl (18%), 0 °C; (b) Na2Se2, aq. NaOH, 40 °C (2 h), 55–63%; (c) SOCl2, DMF, reflux (1 h), >95%; (d) 2-(4-aminophenyl)acetic
acid, Et3N, CH3CN, 0 °C (1 h) to 25 °C
(3 h), 72–76%; (e) (Ph)3P+CH2CH2NH2, DCC, 0 °C (1 h) to 25 °C
(4 h), 80–85%.To date, several methods
for delivery of drugs into mitochondria have been developed, including
their derivatization with certain peptides or with a triphenylphosphonium
group ((Ph)3P+).[21] Since mitochondria maintain a negative potential, the positive charge
of the (Ph)3P+ group drives attached molecules
inside the matrix and toward a diffusion equilibrium, thus affording
up to a thousand-fold accumulation of the drug in mitochondria vs
cytosol. The accumulation of organic cations in mitochondria may also
be mediated by proteins such as the 2-oxoglutarate carrier.[22] Previous studies have shown that MitoPeroxidase
1 is taken up by isolated mitochondria, catalyzes the breakdown of
H2O2 in the presence of thiols, and inhibits
apoptosis induced by oxidants.[20] In agreement
with the reactions presented in Scheme 1, incubation
(5 min; t = 25 °C) of MitoPeroxidase 2 (15 μM;
Figure 1A) and 6,8-bis(sulfanyl)octanoic acid
(dihydrolipoic acid; DHLA; 15 μM) in He-deaerated methanol led
to the formation of a selanyl-benzamide (Figure 1B), which readily reduced 13S-hydroperoxy-9Z,11E-octadecadienoic acid (10 μM;
ROOH; Figure 1C) to the corresponding alcohol
(ROH; tincubation = 5 min; 25 °C;
Figure 1D; MS/MS spectra of both ROOH and ROH
are included in Supporting Information).
Similarly, the selanyl-benzamide reduced hydroperoxides of CL (Supporting Information).
Figure 1
Mass-spectral analysis
of the thiol-dependent reduction of ROOH by MitoPeroxidase 2. DHLA
reduced MitoPeroxidase 2 (A) to selanyl-benzamide (B), which reacted
with ROOH (C) to afford ROH (D). The mass spectra in A and B exhibit
isotopic distribution characteristics for the Se isotopes.[20]
Mass-spectral analysis
of the thiol-dependent reduction of ROOH by MitoPeroxidase 2. DHLA
reduced MitoPeroxidase 2 (A) to selanyl-benzamide (B), which reacted
with ROOH (C) to afford ROH (D). The mass spectra in A and B exhibit
isotopic distribution characteristics for the Se isotopes.[20]Though the benzoselenazol ring is a common pharmacophore
for ebselen and MitoPeroxidases 1 and 2, several factors may differentiate
the pharmacological effect of these compounds. In contrast to ebselen,
which accumulates in the ER, MitoPeroxidases 1 and 2 are expected
to compartmentalize to mitochondria to reach millimolar concentrations.[23] In addition, the conjugated aromatic system
of MitoPeroxidase 1 is extended to the phenolic oxygen, and thus,
its Se–N bond is more polarized. This is likely to facilitate
the conversion of MitoPeroxidase 1 to a selenenyl sulfide (reaction 1 → 2), which may result in an increased
toxicity due to enhanced oxidation of cellular thiols.[24] However, weakening of the Se···O=C<
interaction in 3 by the electron-withdrawing effect of
the phenolic oxygen may increase the GPx activity of the parent benzoselenazol.[25,26]Figure 2A depicts the toxicity of ebselen
and MitoPeroxidases 1 and 2 in mouse embryonic cells (MEC). In contrast
to ebselen and MitoPeroxidase 2, the toxicity of MitoPeroxidase 1
sharply increased in the concentration range of 10 to 20 μM.
Comparable toxicity with MitoPeroxidase 2 was observed at ∼40
μM concentration, while ebselen did not exhibit any significant
toxicity in this concentration range.
Figure 2
Toxicity (A) and radiomitigative properties
(B) of ebselen and MitoPeroxidases 1 and 2. (A,B) Cell death was assessed
flow-cytometrically by analysis of the externalization of phosphatidylserine.
(B) Cells were exposed to IR and then treated with selenazols. The
results represent the mean ± SD (n = 3; *p < 0.05).
Toxicity (A) and radiomitigative properties
(B) of ebselen and MitoPeroxidases 1 and 2. (A,B) Cell death was assessed
flow-cytometrically by analysis of the externalization of phosphatidylserine.
(B) Cells were exposed to IR and then treated with selenazols. The
results represent the mean ± SD (n = 3; *p < 0.05).We next assessed the radio-mitigative properties of the three
benzoselenazols. Exposure of MEC to γ-irradiation (10 Gy) resulted
in ∼28% cell death (Figure 2B), whereas
treatment with MitoPeroxidases 1 and 2 (but not ebselen), prior to
or 30 min postirradiation, afforded radioprotection/mitigation. MitoPeroxidase
1 exerted ∼25% radioprotection/mitigation, while at concentrations
higher than 10 μM its toxicity prevailed the radioprotective
effect. In contrast, 20 μM MitoPeroxidase 2 afforded ∼50%
radioprotection/mitigation. In this model system, MitoPeroxidase 2
acted as a potent inhibitor of radiation-induced activation of caspase
3 (Figure 3), an executioner caspase in apoptosis.
Treatment of irradiated MEC with 3-hydroxypropyl(triphenyl)phosphonium
chloride, which structurally mimics the triphenylphosphonium moieties
of MitoPeroxidases 1 and 2, did not afford any radiomitigation (data
not shown).
Figure 3
MitoPeroxidase 2 impedes the activity of caspase 3 in MEC. Cells
were exposed to IR (10 Gy) and then treated with 20 μM MitoPeroxidase
2 as indicated in Figure 2. Caspase 3 activity
was determined by EnzChek Caspase 3 Assay Kit (Z-DEVD-AMC substrate;
Life Technologies, Grand Island, NY). The results represent the mean
+ SD (n = 3).
MitoPeroxidase 2 impedes the activity of caspase 3 in MEC. Cells
were exposed to IR (10 Gy) and then treated with 20 μM MitoPeroxidase
2 as indicated in Figure 2. Caspase 3 activity
was determined by EnzChek Caspase 3 Assay Kit (Z-DEVD-AMC substrate;
Life Technologies, Grand Island, NY). The results represent the mean
+ SD (n = 3).We further assessed whether the in vitro radiomitigative
effect of MitoPeroxidase 2 was translated into an in vivo effect.
Groups of 15 mice were treated with MitoPeroxidase 2 i.v. at 24 h
after WBI. As shown in Figure 4, at two different
radiation doses, administration of MitoPeroxidase 2 afforded an increase
in survival.
Figure 4
Radiomitigative properties of MitoPeroxidase 2 administered
24 h after exposure to γ-rays in mice (n =
15 mice per group).
Radiomitigative properties of MitoPeroxidase 2 administered
24 h after exposure to γ-rays in mice (n =
15 mice per group).In conclusion, the data
presented herein indicate that MitoPeroxidase 2 acts as a potent radiation
mitigator. Our data complement previous studies on the medicinal chemistry
of ebselen within the context of radiomitigation upon late, 24 h postirradiation
treatment. This is an important pharmacological advantage, as IR damage
to organisms is often the result of accidents, whereby immediate post-IR
treatment may be impractical.
Authors: Hülya Bayir; Valerian E Kagan; Grigory G Borisenko; Yulia Y Tyurina; Keri L Janesko; Vincent A Vagni; Timothy R Billiar; Deborah L Williams; Patrick M Kochanek Journal: J Cereb Blood Flow Metab Date: 2005-06 Impact factor: 6.200
Authors: Detcho A Stoyanovsky; Zhentai Huang; Jianfei Jiang; Natalia A Belikova; Vladimir Tyurin; Michael W Epperly; Joel S Greenberger; Hülya Bayir; Valerian E Kagan Journal: ACS Med Chem Lett Date: 2011-11-10 Impact factor: 4.345
Authors: Michael W Epperly; J A Melendez; Xichen Zhang; Suhua Nie; Linda Pearce; James Peterson; Darcy Franicola; Tracy Dixon; Benjamin A Greenberger; Paavani Komanduri; Hong Wang; Joel S Greenberger Journal: Radiat Res Date: 2009-05 Impact factor: 2.841
Authors: R Yahyapour; E Motevaseli; A Rezaeyan; H Abdollahi; B Farhood; M Cheki; S Rezapoor; D Shabeeb; A E Musa; M Najafi; V Villa Journal: Clin Transl Oncol Date: 2018-01-09 Impact factor: 3.405
Authors: Heeren M Gordhan; Stephen L Patrick; Maria I Swasy; Amber L Hackler; Mark Anayee; Jennifer E Golden; James C Morris; Daniel C Whitehead Journal: Bioorg Med Chem Lett Date: 2016-12-10 Impact factor: 2.823
Authors: Vijayalakshmi Sridharan; John W Seawright; Francis J Antonawich; Merrill Garnett; Maohua Cao; Preeti Singh; Marjan Boerma Journal: Radiat Res Date: 2017-02-23 Impact factor: 2.841
Authors: Jim Küppers; Anna Christina Schulz-Fincke; Jerzy Palus; Mirosław Giurg; Jacek Skarżewski; Michael Gütschow Journal: Pharmaceuticals (Basel) Date: 2016-07-08